Trial Profile
Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Ixazomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms HOVON 143 MM
- 12 Dec 2023 Results analyzing cell subsets related to frailty status, their predictive value for treatment outcome, and their dynamics during treatment, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing dynamics of frailty scores and impact on clinical outcome of non-transplant eligible patients with NDMM (NTE-NDMM) included in this study presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Jun 2023 Results (n=65) assessing the efficacy and tolerability of Ixazomib-Daratumumab-lowdose dexamethasone (IDd) in intermediate-fit NTE-NDMM patients. presented at the 28th Congress of the European Haematology Association